Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101

PURPOSE: The ideal duration of adjuvant chemotherapy for patients with lower risk primary breast cancer is not known. Cancer and Leukemia Group B trial 40101 was conducted using a phase III factorial design to define whether six cycles of a chemotherapy regimen are superior to four cycles. We also s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Shulman, Lawrence N., Cirrincione, Constance T., Berry, Donald A., Becker, Heather P., Perez, Edith A., O'Regan, Ruth, Martino, Silvana, Atkins, James N., Mayer, Erica, Schneider, Charles J., Kimmick, Gretchen, Norton, Larry, Muss, Hyman, Winer, Eric P., Hudis, Clifford
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2012
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3494835/
https://ncbi.nlm.nih.gov/pubmed/22826271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.40.6405
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados